Home > Journals > Minerva Medica > Past Issues > Articles online first > Minerva Medica 2021 May 10

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Medica 2021 May 10

DOI: 10.23736/S0026-4806.21.07527-3

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Gut microbiota and cardiovascular diseases axis: a review

Dora C. MOLDOVAN 1, 2, Abdulrahman ISMAIEL 1, 3 , Sharmila FAGOONEE 4, Rinaldo PELLICANO 5, Ludovico ABENAVOLI 6, Dan L. DUMITRASCU 1, 3

1 Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; 2 Department of Internal Medicine, Regional Institute of Gastroenterology and Hepatology O. Fodor, Cluj-Napoca, Romania; 3 2nd Department of Internal Medicine, Cluj-Napoca, Romania; 4 Institute of Biostructure and Bioimaging, National Research Council, Molecular Biotechnology Center, Turin, Italy; 5 Unit of Gastroenterology, Molinette-SGAS Hospital, Città della Salute e della Scienza, Turin, Italy; 6 Department of Health Sciences, University Magna Graecia, Catanzaro, Italy


PDF


Gut microbiota, a term that includes microorganisms present in the gastrointestinal tract, has become very attractive lately due to its propensity to act as a virtual organ with endocrine functions, generating various bio-active metabolites, while playing an important role in human health and diseases, including cardiovascular diseases (CVDs). Focusing on the latter field, gastrointestinal dysbiosis, that is the imbalance in the gut microbiota composition, has been linked to various pathologies such as hypertension, atherosclerosis, myocardial infarction and heart failure. Several pathways were demonstrated to play a role in the complex and intertwined association between the gut microbiota and host, including metabolic endotoxemia, alteration of pattern recognition receptors and short-chain fatty acids, uremic toxins, bile acids and trimethylamine-N-oxide levels, leading to CVDs. Understanding these pathways can allow to identifying metabolites that could be useful predictors for detecting incipient CVDs stages and potential therapeutic targets. In this review, we summarize the pathways associating the gut microbiota with CVDs.


KEY WORDS: Diet; Cardiovascular events; Liver; Steatosis; Dysbiosis

top of page